About Generate Biomedicines, Inc.
Generate Biomedicines, Inc. (GENB) is a Healthcare company in the Pharmaceutical Preparations industry with a market capitalisation of $2.2B.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Market cap
- $2.2B
- Shares outstanding
- 128.4M
Financial health: Weak4.3/10
3 strengths, 4 concerns. Weakest points: gross margin, net margin, free cash flow and 1 more.
- Debt to equity: -0.11 (Strong, benchmark < 0.5) — Debt of -0.11x equity is conservative against the 0.5x benchmark. It has deteriorated over the last 2 years.
- Net debt vs cash flow: 0.0y (Strong, benchmark < 4 years) — Holds more cash than debt ($153.0M net cash).
- Current ratio: 2.85 (Strong, benchmark > 1.5) — Short-term assets cover 2.85x short-term liabilities, against Graham's 1.5x floor. It has deteriorated over the last 2 years.
- Gross margin: 0.0% (Concern, benchmark > 40%) — Keeps 0.0% of revenue after the direct cost of sales, well short of the > 40% mark.
- Net margin: 0.0% (Concern, benchmark > 10%) — Turns 0.0% of revenue into profit, well short of the > 10% mark.
- Free cash flow: -$204.1M (Concern, benchmark positive) — Burned $204.1M of cash after capital spending, so operations did not fund themselves. It has deteriorated over the last 2 years.
- Revenue growth: -37.7% (Concern, benchmark > 10%) — Revenue changed -37.7% year on year, well short of the > 10% mark.